Navigation Links
AMT Provides Business Update for the Third Quarter 2009
Date:11/18/2009

on. AMT employed 88 persons as of September 30, 2009. Total expenses in the third quarter of 2009 were EUR4.4 million compared to EUR4.7 million in the same period last year.

(*) The Company's cash position is composed of cash and cash equivalents.

Material events after September 30, 2009

On November 11, 2009 AMT announced that it has successfully treated Duchenne muscular dystrophy (DMD) in an animal model with its proprietary gene therapy. The proof of concept studies were performed in collaboration with the group of Professor Irene Bozzoni (University of Rome, La Sapienza, Italy) and demonstrated efficacy in the heart as well as in skeletal muscles. In a previous study, AMT's gene therapy approach was shown to be successful in the treatment of diseased human muscle cells obtained from biopsies of DMD patients. These data establish a robust basis for AMT's therapeutic approach to DMD.

The ongoing trial with Glybera(R) for lipoprotein lipase deficient (LPLD) patients in Canada was closed for patient recruitment on October 30, 2009 with 5 patients dosed. AMT is well on track to file for regulatory approval for Glybera(R) within the next three months. The main aim of the ongoing trial is to gain further insight in the mechanism of action of Glybera(R), and data obtained from this trial will further strengthen the Glybera(R) data package that will be filed with the EMEA.

On November 17, 2009, updated safety and efficacy data on Glybera(R) from the first two clinical studies was presented at the meeting of the American Heart Association in Orlando. These data confirm the sizeable decrease in pancreatitis incidence after therapy with Glybera(R) and confirm its excellent safety profile.

On October 29, 2009, AMT and Progenika Biopharma announced that they have entered into a development and commercialization agreement for LPLchipTM, a diagnostic tool to rapidly diagnose patient
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
2. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. Microbix Biosystems Provides a Corporate Update
5. Alexandria Real Estate Equities, Inc. Provides Update
6. SemBioSys provides an update on Botaneco
7. MacuSight(R) Provides Clinical Development Update for Perceiva(TM)
8. New nanostructure technology provides advances in eyeglass, solar energy performance
9. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
10. Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
11. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Research and Markets  has announced the addition of ... Business Report" report to their offering. ... Cells (SOFCs) in US$ Thousands. The report provides separate comprehensive ... Europe , Asia-Pacific , and ... the period 2012 through 2020. Market data and analytics are ...
(Date:8/19/2014)... Md. , Aug. 19, 2014 CSSi, ... research industry, recently announced the formation of the company,s ... to announce the addition of Dr. William E. ... - http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, ... a variety of therapeutic areas and set strategic goals ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 Sales Horizons, ... of its online sales skills training course ... skills. , MedTech clinical staff spend the majority of ... hospital, standalone medical center, or physician practice – providing ... But why stop there? Sales Horizons believes clinical staff ...
(Date:8/18/2014)... Md. , Aug. 18, 2014 /PRNewswire/ ... maker of advanced consumer medical devices said ... was interviewed by CEOLIVE.TV as part ... The entire interview is available at ... Dr. Kotak explains to investors the unique ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... the most promising biotech start-up company at the recent ... a proprietary process to convert wastewater from food and ... was given top honors out of 22 total entries ... from the sponsoring Colorado law firm of Dorsey & ...
... 8 Prosolia, Inc. introduces a new,advanced Omni Spray Ion ... Omni Spray 2-D Ion Source has an automated,surface platform which ... up to 76 mm by 114 mm, which is the ... The Omni Spray 2-D Ion Source ...
... leader in,workforce and recruitment solutions announced today that it ... company with its prestigious 2008,Supplier of Excellence Award. ... suppliers, this is the first time they have ever ... are thousands of suppliers of,products and services to Alcon ...
Cached Biology Technology:Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 2Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 3Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 4Oberon FMR Wins Top Prize at BioWest 2008 Venture Showcase Competition 5Prosolia to Introduce Omni Spray(R) Ion Source in 2-D Format 2Adecco Receives Honor From Alcon Laboratories 2
(Date:8/20/2014)... 4,000 members, it triggers an important first stage in ... of comb used for rearing male reproductive, called drones. ... and Behaviour at Cornell University, led by Michael Smith, ... The results are published in Springer,s journal Naturwissenschaften ... isn,t always a honeybee colony,s top priority. Early ...
(Date:8/20/2014)... -- The second annual Biometrics UnPlugged Executive Summit, set ... on September 15, 2014, will feature ... Strategy at Samsung, and Philippe de Raet, Vice President, ... year,s event is Mobility at the Crossroads of ... Mobility at the Crossroads of Commerce & Privacy ...
(Date:8/19/2014)... Wind and ... amount of electricity is to be produced with renewable energy ... stored during productive periods so that these fluctuations can be ... for the purpose. Science and industry are therefore working on ... that used to be too expensive or unsophisticated to be ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3
... Xanex or Xanax? Or maybe Zantac? If you're a health ... , An estimated 1.3 million people in the United States ... U.S. Federal Drug Administration (FDA) has been working to reduce ... in which a patient needed an injection of Narcan but ...
... Genes & Development, Dr. Mary Ellen Perry and colleagues ... for cancer therapies. , The p53 tumor suppressor plays ... strategies aim to activate p53 in order to curb ... and therefore an attractive target to modulate p53 activity ...
... death by suicide generally decreases in the weeks after ... study led by Group Health Cooperative researchers and published ... Psychiatry. The study also found that the risk of ... less than the risk posed by older medications. ...
Cached Biology News:Computer scientist sorts out confusable drug names 2Suicide risk does not increase when adults start using antidepressants, study finds 2
... PCR System is the only PCR system ... and every time. It provides accuracy, consistency, ... source or the property of the DNA ... Enzyme Mix, a unique blend of thermostable ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
Biology Products: